HAYWARD, Calif., June 8 /PRNewswire/ -- Acologix, Inc., a privately-held biopharmaceutical company, announced today that two preclinical studies demonstrated that AC-100, its novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, promoted bone formation and maturation in animal models. The data was presented as an oral presentation at the 16th Annual Meeting of the European Orthopedic Research Society in Bologna, Italy.
